Prof. Maddocks describes the key prognostic factors that indicate high risk of inferior outcomes in patients with FL1/3 Next Interview
Dr Batlevi reviews the novel and emerging treatment strategies for patients with R/R FL2/3 Next Interview
Dr Sehn explains the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL and describes its potential implications for daily clinical practice3/3 Take CME Test
Overview & Learning Objectives
In this activity, leading lymphoma specialists provide updates on the different prognostic indices and factors and novel treatment strategies, such as PI3K and EZH2 inhibition, for patients with relapsed/refractory follicular lymphoma.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of hematologists and oncologists involved in the management of follicular lymphoma.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 29 March 2021. Date credits expire: 29 March 2022.
After watching this activity, participants should be better able to:
- Evaluate the key prognostic factors that indicate high risk of inferior outcomes in patients with FL
- Evaluate novel and emerging treatment strategies for patients with R/R FL
- Translate the latest clinical data for EZH2 and PI3K inhibitors in patients with R/R FL into clinical practice